hVIVO (LON:HVO) Issues Earnings Results

hVIVO (LON:HVO) posted its earnings results on Thursday. The company reported GBX 1.69 ($0.02) earnings per share for the quarter, Digital Look Earnings reports. hVIVO had a return on equity of 47.93% and a net margin of 25.96%.

hVIVO Stock Performance

LON:HVO opened at GBX 15.09 ($0.19) on Thursday. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The business has a fifty day simple moving average of GBX 16.22 and a two-hundred day simple moving average of GBX 20.93. hVIVO has a 1 year low of GBX 12.60 ($0.16) and a 1 year high of GBX 31 ($0.40). The company has a market capitalization of £106.77 million, a P/E ratio of 6.22 and a beta of 0.97.

Insiders Place Their Bets

In other hVIVO news, insider Yamin Mo’ Khan sold 3,062,246 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.22), for a total value of £520,581.82 ($665,195.27). Company insiders own 14.03% of the company’s stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.